Potential of bacteriophages as a therapeutic alternative to antibiotics: Scientometric Analysis
DOI:
https://doi.org/10.18041/2619-4465/interfaces.1.13391Keywords:
Bacteriophage, Medicine, Phage therapy, Scientometrics, Bacterial resistanceAbstract
This scientometric article is based on an analysis of the relevance of bacteriophages as a therapeutic alternative to antibiotics, in light of the growing resistance of microbial agents. For this study, two fundamental databases were used: Scopus and Web of Science, both of which are recognized for compiling current and relevant research. These databases provided effective information on how bacteriophages have evolved from being merely infectious agents to becoming a therapeutic alternative against bacterial resistance. To filter the large number of articles initially retrieved from these databases, a preprocessing step was applied to extract the most relevant publications, resulting in an organized Excel sheet. The analyzed results focused on the total number of publications per year, the most cited authors, the most influential research institutions, and the countries with the highest academic production. This analysis allowed for the identification of global trends in phage therapy research, highlighting its potential to address one of the most critical challenges in modern medicine: bacterial multi-resistance.
Downloads
References
[1]M. Palma and B. Qi, “Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections,” Infectious Disease Reports, vol. 16, no. 6, pp. 1127–1181, Nov. 2024, doi: 10.3390/idr16060092.
[2]M. Passerini, F. Petri, and G. A. Suh, “Phage Therapy for Cardiac Implantable Electronic Devices and Vascular Grafts: A Targeted Literature Review,” Pathogens, vol. 13, no. 5, May 2024, doi: 10.3390/pathogens13050424.
[3]J. Tsonos, D. Vandenheuvel, Y. Briers, H. De greve, J. Hernalsteens, and R. Lavigne, “Hurdles in bacteriophage therapy: Deconstructing the parameters,” Veterinary Microbiology, vol. 171, no. 3–4, pp. 460–469, Jul. 2014, doi: 10.1016/j.vetmic.2013.11.001.
[4]T. Faltus, “The Medicinal Phage—Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation,” Viruses, vol. 16, no. 3, p. 443, Mar. 2024, doi: 10.3390/v16030443.
[5]M. Koncz et al., “Website.” [Online]. Available: https://doi.org/10.1016/j.cell.2024.09.009
[6]F. Tristán, O. Jolien, R. Tiphaine, B. Cécile, M. Thomas, and M. Willem-Jan, “Website.” [Online]. Available: https://doi.org/10.1530/EOR-24-0042
[7]S. Valencia, M. Zuluaga, A. Franco, M. Osorio, and S. Betancour, “Systematic review and bibliometric analysis of the metabolome found in human breast milk from healthy and gestational diabetes mellitus mothers,” Nova, vol. 21, no. 41, Dec. 2023, doi: 10.22490/24629448.7545.
[8]J. G. Saurith Moreno, D. C. Blanco Galan, S. Mindiola Garizado, and J. F. Ruiz Muñoz, “Optimization of marketing strategies employing LLMs: A systematic review,” Lúmina, vol. 25, no. 2, p. E0058, Aug. 2024, doi: 10.30554/lumina.v25.n2.5147.2024.
[9]S. Maestre and A. Torrijos, “Vista de Sistemas agrivoltaicos: una contribución a la sostenibilidad.” Accessed: Jun. 07, 2025. [Online]. Available: https://revistas.unilibre.edu.co/index.php/interfaces/article/view/12713/12750
[10]A. Britto and M. Delcides, “Vista de Análisis cienciométrico de la relación entre inteligencia artificial eingeniería de datos: tendencias, colaboración y evolución.” Accessed: Jun. 07, 2025. [Online]. Available: https://revistas.unilibre.edu.co/index.php/interfaces/article/view/12714/12751
[11]A. S. Nilsson, “Phage therapy—constraints and possibilities,” Upsala Journal of Medical Sciences, vol. 119, no. 2, pp. 192–198, Mar. 2014, doi: 10.3109/03009734.2014.902878.
[12]E. M. Barbu, K. C. Cady, and B. Hubby, “Phage Therapy in the Era of Synthetic Biology,” Cold Spring Harb Perspect Biol, vol. 8, no. 10, Oct. 2016, doi: 10.1101/cshperspect.a023879.
[13]J.-P. Pirnay, “Phage Therapy in the Year 2035,” Front. Microbiol., vol. 11, p. 538375, Jun. 2020, doi: 10.3389/fmicb.2020.01171.
[14]A. Górski et al., “Phage Therapy in Prostatitis: Recent Prospects,” Front. Microbiol., vol. 9, p. 379263, Jun. 2018, doi: 10.3389/fmicb.2018.01434.
[15]T. S. Brady et al., “Bystander Phage Therapy: Inducing Host-Associated Bacteria to Produce Antimicrobial Toxins against the Pathogen Using Phages,” Antibiotics, vol. 7, no. 4, p. 105, Dec. 2018, doi: 10.3390/antibiotics7040105.
[16]V. Y. Ooi and T.-Y. Yeh, “Recent Advances and Mechanisms of Phage-Based Therapies in Cancer Treatment,” Int J Mol Sci, vol. 25, no. 18, Sep. 2024, doi: 10.3390/ijms25189938.
[17]D. M. Pacia, B. L. Brown, T. Minssen, and J. J. Darrow, “CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations,” J Law Biosci, vol. 11, no. 1, p. lsad030, Jan. 2024, doi: 10.1093/jlb/lsad030.
[18]M. G. Martinet, M. Thomas, J. Bojunga, M. W. Pletz, M. J. G. T. Vehreschild, and S. Würstle, “The landscape of biofilm models for phage therapy: mimicking biofilms in diabetic foot ulcers using 3D models,” Front Microbiol, vol. 16, p. 1553979, Feb. 2025, doi: 10.3389/fmicb.2025.1553979.
[19]F. Ferrara et al., “Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer,” Proc Natl Acad Sci U S A, vol. 113, no. 45, pp. 12786–12791, Nov. 2016, doi: 10.1073/pnas.1615400113.
[20]S. T. Abedon, “Information Phage Therapy Research Should Report,” Pharmaceuticals (Basel), vol. 10, no. 2, Apr. 2017, doi: 10.3390/ph10020043.
[21]M. H. Oh, J. H. Yu, I. Kim, and Y. S. Nam, “Genetically Programmed Clusters of Gold Nanoparticles for Cancer Cell-Targeted Photothermal Therapy,” Oct. 2015, doi: 10.1021/acsami.5b07029.
[22]J. Qu, J. Zou, J. Zhang, J. Qu, and H. Lu, “Phage therapy for extensively drug resistant infection: case report and evaluation of the distribution of phage and the impact on gut microbiome,” Front Med (Lausanne), vol. 11, p. 1432703, Dec. 2024, doi: 10.3389/fmed.2024.1432703.
[23]X. Zheng et al., “Antibacterial activity evaluation of a novel K3-specific phage against Acinetobacter baumannii and evidence for receptor-binding domain transfer across morphologies,” Virol Sin, vol. 39, no. 5, pp. 767–781, Oct. 2024, doi: 10.1016/j.virs.2024.08.002.
[24]A. Kapoor, S. B. Mudaliar, V. G. Bhat, I. Chakraborty, A. S. B. Prasad, and N. Mazumder, “Phage therapy: A novel approach against multidrug-resistant pathogens,” 3 Biotech, vol. 14, no. 10, pp. 1–20, Sep. 2024, doi: 10.1007/s13205-024-04101-8.
[25]D. Olawade et al., “Phage therapy: A targeted approach to overcoming antibiotic resistance,” Microbial Pathogenesis, vol. 197, p. 107088, Dec. 2024, doi: 10.1016/j.micpath.2024.107088.
[26]N. M. Hitchcock et al., “Current Clinical Landscape and Global Potential of Bacteriophage Therapy,” Viruses, vol. 15, no. 4, p. 1020, Apr. 2023, doi: 10.3390/v15041020.
[27]J. Monnerat et al., “Antibacterial effect of genetically-engineered bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA on dentin infected with antibiotic-resistant Enterococcus faecalis,” Archives of Oral Biology, vol. 82, pp. 166–170, Oct. 2017, doi: 10.1016/j.archoralbio.2017.06.005.
[28]J. D. Jones et al., “How to: assess patient suitability for unlicensed phage therapy in the United Kingdom,” Clin Microbiol Infect, vol. 31, no. 1, pp. 57–61, Jan. 2025, doi: 10.1016/j.cmi.2024.07.022.
[29]H. J. Stacey, S. De Soir, and J. D. Jones, “The Safety and Efficacy of Phage Therapy: A Systematic Review of Clinical and Safety Trials,” Antibiotics (Basel), vol. 11, no. 10, Sep. 2022, doi: 10.3390/antibiotics11101340.
[30]A. Steele, H. J. Stacey, S. de Soir, and J. D. Jones, “The Safety and Efficacy of Phage Therapy for Superficial Bacterial Infections: A Systematic Review,” Antibiotics (Basel), vol. 9, no. 11, Oct. 2020, doi: 10.3390/antibiotics9110754.
[31]A. L. Clarke, S. De Soir, and J. D. Jones, “The Safety and Efficacy of Phage Therapy for Bone and Joint Infections: A Systematic Review,” Antibiotics (Basel), vol. 9, no. 11, Nov. 2020, doi: 10.3390/antibiotics9110795.
[32]E. J. Vainio, H. Anany, and P. Hyman, “Editorial: Beyond humans-Virus therapy for pathogens of animals and plants,” Front Microbiol, vol. 13, p. 1127901, 2022, doi: 10.3389/fmicb.2022.1127901.
[33]S. Mattila, P. Ruotsalainen, and M. Jalasvuori, “On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy,” Front Microbiol, vol. 6, p. 1271, Nov. 2015, doi: 10.3389/fmicb.2015.01271.
[34]J. Doss, K. Culbertson, D. Hahn, J. Camacho, and N. Barekzi, “A Review of Phage Therapy against Bacterial Pathogens of Aquatic and Terrestrial Organisms,” Viruses, vol. 9, no. 3, Mar. 2017, doi: 10.3390/v9030050.
[35]C. Rohde et al., “Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains,” Viruses, vol. 10, no. 4, Apr. 2018, doi: 10.3390/v10040178.
[36]G. Zou et al., “Improving the safety and efficacy of phage therapy from the perspective of phage-mammal interactions,” FEMS Microbiol Rev, vol. 47, no. 4, p. fuad042, Jul. 2023, doi: 10.1093/femsre/fuad042.
[37]N. A. El-Wafai et al., “Evaluation of hematological and blood biochemical indices in cultured Nile tilapia (Oreochromis niloticus) as affected by using phage therapy against Pseudomonas aeruginosa,” Annals of Animal Science, vol. 24, no. 2, pp. 465–477, Apr. 2024, doi: 10.2478/aoas-2024-0005.
[38]J. E. Hirsch, “An index to quantify an individual’s scientific research output,” Aug. 2005, doi: 10.1073/pnas.0507655102.
[39]D. Katarzyna, D. Krystyna, and S. Abedon, “Phage Therapy: The Pharmacology of Antibacterial Viruses.” Accessed: Jun. 07, 2025. [Online]. Available: https://doi.org/10.21775/cimb.040.081
[40]S. T. Abedon, K. M. Danis-Wlodarczyk, and D. R. Alves, “Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?,” Pharmaceuticals, vol. 14, no. 11, p. 1157, Nov. 2021, doi: 10.3390/ph14111157.
[41]S. T. Abedon, K. M. Danis-Wlodarczyk, and D. J. Wozniak, “Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth,” Pharmaceuticals, vol. 14, no. 10, p. 1019, Oct. 2021, doi: 10.3390/ph14101019.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Interfaces
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
